These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34165911)

  • 41. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study.
    Yoon JA; Jeong Y; Lee J; Lee DJ; Lee KN; Shin YB
    BMC Neurol; 2024 Jun; 24(1):210. PubMed ID: 38902631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluator Training and Reliability for SMA Global Nusinersen Trials1.
    Glanzman AM; Mazzone ES; Young SD; Gee R; Rose K; Mayhew A; Nelson L; Yun C; Alexander K; Darras BT; Zolkipli-Cunningham Z; Tennekoon G; Day JW; Finkel RS; Mercuri E; De Vivo DC; Baldwin R; Bishop KM; Montes J
    J Neuromuscul Dis; 2018; 5(2):159-166. PubMed ID: 29865090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
    Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
    BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
    Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y
    J Neurol; 2024 Jul; ():. PubMed ID: 38954034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
    Kessler T; Sam G; Wick W; Weiler M
    Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nusinersen treatment of older children and adults with spinal muscular atrophy.
    Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
    Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
    Hiebeler M; Abicht A; Reilich P; Walter MC
    J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3.
    Côté I; Hodgkinson V; Nury M; Bastenier-Boutin L; Rodrigue X
    Can J Neurol Sci; 2024 Mar; ():1-10. PubMed ID: 38532567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nusinersen Treatment in Adults With Spinal Muscular Atrophy.
    Duong T; Wolford C; McDermott MP; Macpherson CE; Pasternak A; Glanzman AM; Martens WB; Kichula E; Darras BT; De Vivo DC; Zolkipli-Cunningham Z; Finkel RS; Zeineh M; Wintermark M; Sampson J; Hagerman KA; Young SD; Day JW
    Neurol Clin Pract; 2021 Jun; 11(3):e317-e327. PubMed ID: 34476123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy.
    Stolte B; Bois JM; Bolz S; Kizina K; Totzeck A; Schlag M; Kleinschnitz C; Hagenacker T
    Eur J Neurol; 2020 Dec; 27(12):2586-2594. PubMed ID: 32781490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 56. Different trajectories in upper limb and gross motor function in spinal muscular atrophy.
    Coratti G; Pera MC; Montes J; Pasternak A; Scoto M; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; De Sanctis R; Mazzone ES; Milev E; Rohwer A; Civitello M; Pane M; Antonaci L; Frongia AL; Sframeli M; Vita GL; DʼAmico A; Mizzoni I; Albamonte E; Darras BT; Bertini E; Sansone VA; Bovis F; Day J; Bruno C; Muntoni F; De Vivo DC; Finkel R; Mercuri E
    Muscle Nerve; 2021 Nov; 64(5):552-559. PubMed ID: 34327716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes.
    Coratti G; Carmela Pera M; Montes J; Scoto M; Pasternak A; Bovis F; Sframeli M; D'Amico A; Pane M; Albamonte E; Antonaci L; Lia Frongia A; Mizzoni I; Sansone VA; Russo M; Bruno C; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; de Sanctis R; Stacy Mazzone E; Milev E; Rohwer A; Civitello M; Darras BT; Bertini E; Day J; Muntoni F; De Vivo DC; Finkel RS; Mercuri E
    Neuromuscul Disord; 2022 Jan; 32(1):36-42. PubMed ID: 34980538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.
    Coratti G; Bovis F; Pera MC; Scoto M; Montes J; Pasternak A; Mayhew A; Muni-Lofra R; Duong T; Rohwer A; Dunaway Young S; Civitello M; Salmin F; Mizzoni I; Morando S; Pane M; Albamonte E; D'Amico A; Brolatti N; Sframeli M; Marini-Bettolo C; Sansone VA; Bruno C; Messina S; Bertini E; Baranello G; Day J; Darras BT; De Vivo DC; Hirano M; Muntoni F; Finkel R; Mercuri E;
    Eur J Neurol; 2024 Aug; 31(8):e16309. PubMed ID: 38656662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study.
    Günther R; Wurster CD; Brakemeier S; Osmanovic A; Schreiber-Katz O; Petri S; Uzelac Z; Hiebeler M; Thiele S; Walter MC; Weiler M; Kessler T; Freigang M; Lapp HS; Cordts I; Lingor P; Deschauer M; Hahn A; Martakis K; Steinbach R; Ilse B; Rödiger A; Bellut J; Nentwich J; Zeller D; Muhandes MT; Baum T; Christoph Koch J; Schrank B; Fischer S; Hermann A; Kamm C; Naegel S; Mensch A; Weber M; Neuwirth C; Lehmann HC; Wunderlich G; Stadler C; Tomforde M; George A; Groß M; Pechmann A; Kirschner J; Türk M; Schimmel M; Bernert G; Martin P; Rauscher C; Meyer Zu Hörste G; Baum P; Löscher W; Flotats-Bastardas M; Köhler C; Probst-Schendzielorz K; Goldbach S; Schara-Schmidt U; Müller-Felber W; Lochmüller H; von Velsen O; ; Kleinschnitz C; Ludolph AC; Hagenacker T
    Lancet Reg Health Eur; 2024 Apr; 39():100862. PubMed ID: 38361750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function.
    Dunaway Young S; Montes J; Glanzman AM; Gee R; Day JW; Finkel RS; Darras BT; De Vivo DC; Gambino G; Foster R; Wong J; Garafalo S; Berger Z;
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.